Every Form 4 that Nautilus Biotechnolgy, Inc. (NAUT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NAUT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NAUT filings page.
Nautilus Biotechnology director Matthew L. Posard received a grant of stock options for 45,000 shares of common stock. The options have an exercise price of $2.28 per share and expire on June 18, 2036. According to the grant terms, one-twelfth of the option vests each month after the grant date, so long as he continues to serve as a “Service Provider” under the company’s 2021 Equity Incentive Plan.
Nautilus Biotechnology director Farzad Nazem received a grant of stock options covering 45,000 shares of common stock. The options have an exercise price of $2.28 per share and expire on June 18, 2036. All 45,000 options are held directly after this grant.
According to the grant’s terms, one-twelfth of the options vest each month following the grant date, as long as Nazem continues to serve as a “Service Provider” under Nautilus’s 2021 Equity Incentive Plan. This creates a 12‑month, time-based vesting schedule tied to ongoing service.
Nautilus Biotechnology, Inc. director Karen Akinsanya received a grant of stock options as part of her compensation. The award covers 45,000 options to buy common stock at an exercise price of $2.28 per share, expiring on June 18, 2036.
These options vest in equal monthly installments over 12 months following the grant date, as long as she continues as a qualifying “Service Provider” under the company’s 2021 Equity Incentive Plan. After this grant, she holds 45,000 stock options directly.
Nautilus Biotechnology director Matthew S. McIlwain received a grant of stock options for 45,000 shares of common stock. These options have an exercise price of $2.28 per share and expire on June 18, 2036. Following this grant, he holds options for 45,000 shares directly.
The options were awarded as compensation, not purchased in the open market, and vest over time. One-twelfth of the options vest each month after the grant date as long as he continues to serve as a qualifying service provider to the company.
Nautilus Biotechnology director Melissa B. Epperly received a grant of stock options covering 45,000 shares of common stock. The options have an exercise price of $2.28 per share and expire on June 18, 2036.
These options vest in equal monthly installments over 12 months, with one-twelfth of the grant vesting each month after the grant date, as long as she continues to serve as a “Service Provider” under the company’s 2021 Equity Incentive Plan. Following this grant, she holds 45,000 stock options directly.
Nautilus Biotechnology, Inc. disclosed that investment funds affiliated with Andreessen Horowitz executed open-market sales of common stock. AH Bio Fund II, L.P. sold 4,615,974 shares of common stock at $2.35 per share, leaving 11,682,032 shares of common stock held indirectly. Andreessen Horowitz LSV Fund II, L.P. sold 384,026 shares of common stock at $2.35 per share, with 971,885 shares of common stock remaining indirectly held. The funds are controlled through general partners AH Equity Partners Bio II, L.L.C. and AH Equity Partners LSV II, L.L.C., whose managing members are Marc Andreessen and Ben Horowitz, and the reporting persons disclaim group status and beneficial ownership beyond any pecuniary interest.
Nautilus Biotechnology, Inc. director and CEO Sujal M. Patel reported an open-market purchase of 25,000 shares of Common Stock at a weighted average price of $2.6095 per share. Following this buy, he directly owns 10,366,721 common shares.
He also reports indirect ownership of 5,280,476 common shares held by PFV I, LLC, for which he is the manager, and 1,814,035 common shares held by the Sujal Patel 2020 Children's Trust, where he and his spouse serve as trustees.
Nautilus Biotechnology reported that its CFO and Treasurer, Anna Mowry, received a grant of stock options covering 160,000 shares of common stock. The options were awarded at an exercise price of $0.00 per share, reflecting a compensatory grant rather than an open-market purchase.
According to the award’s vesting terms, 25% of the options will vest on the one-year anniversary of the vesting commencement date of January 1, 2026, with the remaining shares vesting in equal monthly installments over the following 36 months, contingent on her continued service as a “Service Provider.”
Mallick Parag reported acquisition or exercise transactions in this Form 4 filing.
Nautilus Biotechnology, Inc. reported that Chief Scientist and 10% owner Parag Mallick was granted stock options covering 280,000 shares of common stock. These options were awarded on March 2, 2026 and are structured as a long-term equity incentive.
The grant vests over time, subject to Mallick’s continued service to the company. Twenty-five percent of the options vest on the one-year anniversary of the January 1, 2026 vesting commencement date, with the remaining options vesting in equal monthly installments over the following thirty-six months.
Nautilus Biotechnology CEO Sujal M. Patel received a grant of 650,000 stock options described as a right to buy shares at an exercise price of $0.0000 per share. According to the vesting terms, 25% of the options vest on the one-year anniversary of the vesting commencement date of January 1, 2026, with the remaining shares vesting in equal monthly installments over the following 36 months, contingent on his continued service.
Nautilus Biotechnology reported that Senior VP of Product Development Sankar Subramanian received a grant of stock options covering 160,000 shares on March 2, 2026. The options have an exercise price of $0.00 per share and represent a new award rather than an open-market purchase.
According to the vesting terms, 25% of the option shares vest on the one-year anniversary of the January 1, 2026 vesting commencement date, with the remaining shares vesting in equal monthly installments over the following 36 months, contingent on continued service as a “Service Provider.”
Nautilus Biotechnology reported that Chief People Officer Gwen E. Weld received a grant of stock options covering 160,000 shares of common stock. The award is classified as a grant or other acquisition and was reported as a derivative security with no purchase price listed per share.
The options vest over time, starting with 25% of the shares vesting on the one-year anniversary of the January 1, 2026 vesting commencement date. The remaining shares vest in equal monthly installments over the following 36 months, contingent on Weld’s continued service to the company.
Nautilus Biotechnology granted General Counsel Matthew B. Murphy a stock option covering 160,000 shares of common stock. The option was awarded at an exercise price of $0.00 per share, so he did not pay anything at grant. Vesting is tied to his continued service: 25% of the option vests on the one-year anniversary of the January 1, 2026 vesting commencement date, with the remaining shares vesting in equal monthly installments over the following 36 months. This award increases his directly held option position to 160,000 shares.
Nautilus Biotechnology Chief Marketing Officer awarded stock options
Nautilus Biotechnology granted Chief Marketing Officer Kentaro Suzuki a stock option to acquire 160,000 shares on March 2, 2026. The option has a $0.00 exercise price and vests over time, starting from a vesting commencement date of January 1, 2026.
One quarter of the option vests on the one-year anniversary of the vesting commencement date, with the remaining shares vesting monthly in equal installments, subject to his continued service with the company.
Nautilus Biotechnology (NAUT) reported an insider share purchase on a Form 4. The company’s Chief Marketing Officer bought 4,000 shares of common stock on 11/06/2025 at $1.49 per share. Following the transaction, the officer beneficially owned 4,000 shares, held directly.